



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

COVID-19 mRNA vaccine-related adenopathy mimicking metastatic melanoma



Peter A Prieto, Kathleen Mannava, Deepak M Sahasrabudhe

A 48-year-old white female patient underwent wide excision and sentinel lymph node biopsy for a T2a melanoma of the left deltoid region at Strong Memorial Hospital of the University of Rochester Medical Center (Rochester, NY, USA) on Dec 11, 2020. Final pathology revealed a negative excision margin and one of two sentinel lymph nodes with micrometastatic disease (with no extracapsular extension); T2aN1 pathological stage IIIA. Staging brain MRI was negative; however, a PET-CT scan showed substantial fluorodeoxyglucose (¹⁸F-FDG) avidity in the contralateral axilla and neck (figure, A) and postoperative changes in the ipsilateral axilla and shoulder (small seroma and biopsy clips from sentinel lymph node biopsy).

Image-guided biopsy of an FDG-avid right axillary lymph node was done on Jan 13, 2021. Histological immunohistochemical stains for melanocytes (Melan-A and SOX10) were negative, which is consistent with a diagnosis of reactive lymphoid tissue. Further questioning of the patient revealed that she had received her first dose of the COVID-19 mRNA vaccine (the vaccine produced by Moderna [Cambridge, MA, USA]) in the right deltoid muscle 5 days prior to the initial staging PET-CT scan.

Her second dose of the vaccine was administered in the right thigh on Jan 28, 2021. A repeat PET-CT scan done 5 days after her second dose of the vaccine revealed resolution of the hypermetabolic right axillary and neck nodes with normal radiographic morphology (figure, B) and the development of hypermetabolic right inguinal and pelvic adenopathy.

Clinicians should be aware of the transient appearance of hypermetabolic regional lymph nodes after injection of the COVID-19 mRNA vaccine and possibly other vaccines. As COVID-19 vaccination programmes expand worldwide, it will be important for oncologists to include history of vaccination in interpreting the results of staging imaging studies.

Contributors

PAP made the clinical diagnosis. PAP and DMS proposed the manuscript. KM made the pathological diagnosis and reviewed the immunohistochemical stains. PAP, KM, and DMS all contributed equally to the drafting the manuscript and writing and editing. All authors developed and approved the manuscript. Written informed consent to publication was obtained.

Declaration of interests

We declare no competing interests.

Copyright © 2021 Elsevier Ltd. All rights reserved.




Figure 1: Fluorodeoxyglucose PET-CT scans

(A) Initial scan 5 days after first dose of the COVID-19 mRNA vaccine (in the right deltoid muscle) and (B) repeat scan after second dose (given in the right thigh). Note resolution of right axillary avidity.

Lancet Oncol 2021; 22: e281

Department of Surgery,
Division of Surgical Oncology
(P A Prieto MD), Department of
Medicine, Division of
Hematology/Oncology
(Prof D M Sahasrabudhe MD),
Wilmot Cancer Center
(P A Prieto,
Prof D M Sahasrabudhe)
and Departments of
Dermatology and Pathology
(K Mannava MD), University of
Rochester Medical Center,
Rochester, NY, USA

Correspondence to:
Dr Peter A Prieto, Department of
Surgery, Division of Surgical
Oncology, University of
Rochester Medical Center,
Rochester, NY 14620, USA
peter_prieto@urmc.rochester.
edu